Tuesday, July 14, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
FDA CLEAREDLED Light Therapy Masks (LED Face Mask Pro FAC08NA, LED Chest Mask Pro FAC09NA) — Guangdong Newdermo Biotech Co., Ltd.2 weeks agoFDA CLEAREDLED Neck Beauty Mask (ZLD-66A,ZLD-90E,ZLD-130,ZLD-180H) — Shenzhen Kaiyan Medical Equipment Co., Ltd.4 weeks agoFDA CLEAREDLUTRONIC GENIUS — Cynosure Lutronic Technology Corporation2 weeks agoFDA CLEAREDPICOSURE WORKSTATION — Cynosure, LLC4 weeks agoFDA CLEAREDHemolase Fiber (Hemo-R-0.40-2.5/Hemo-R-0.60-2.5/Hemo-R-0.40-1.8/Hemo-R-0.60-1.8) — Micro-Energy Medical Technology Co., Ltd.4 weeks agoFDA CLEAREDCoolSeal Generator® (CSL-200-90) — Hologic, Inc.4 weeks agoFDA CLEAREDLED Light Therapy Mask (K9C-TK, K9C-K, K9P-YK, K9P-K, FM-03BK, FM-09K) — Guangdong Newdermo Biotech Co., Ltd.4 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Business & M&A

Sisram Medical Restructures DAXXIFY China Deal With Fosun — Supply Chain Shift Signals Market Consolidation

The toxin maker reshuffles its Asia-Pacific distribution as competition intensifies.

Image: Inside MedSpa

Sisram Medical, which markets DAXXIFY (daxibotulinumtoxinA-lanm, a long-acting neuromodulator), has restructured its China distribution agreement with Fosun, a connected entity. The move reflects Sisram's strategy to optimize supply-chain economics and market access in Asia-Pacific, where neuromodulator demand is accelerating but pricing remains highly competitive.

Scaled manufacturing in Asia could enable DAXXIFY to undercut Botox and Dysport pricing within 24 months.

DAXXIFY is FDA-approved and marketed in the U.S. as a longer-acting alternative to Botox, with clinical data supporting 6-month duration. Sisram's restructuring in China—one of the world's largest aesthetic markets—suggests the company is preparing for scaled manufacturing and distribution. For U.S. practices, DAXXIFY remains a secondary player, but the China deal restructuring signals Sisram's intent to build global scale. If Sisram achieves significant volume in Asia, per-unit manufacturing costs will decline, enabling more aggressive U.S. pricing and rebate offers. Practices should monitor DAXXIFY's rebate programs; a long-acting toxin with improving economics could become a credible third option alongside Botox and Dysport within 24 months.

Source: original report ↗

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa Pro

    By the time it's news, it's too late.

    The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

    Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
    The twice-a-week intelligence brief Go Pro · $20/mo